Aging populations worldwide face increasing levels of chronic disease that present unmet needs matching Olympus’ competitive strengths, as well as opportunities to continue providing solutions for colorectal cancer, benign prostatic hyperplasia, urological stone disease, urinary disease, and lung cancer. Olympus will focus on the disease states where it can maximize its positive impact, including those targeted by its Gastrointestinal, Urology, and Respiratory business areas. Focus the portfolio on disease states where Olympus can maximize impact.Three major principles guide the company’s approach: The medtech leader’s approach involves greater focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases that will increasingly impact the global population, as well as more focused investment in next-generation technologies that will enhance patient care pathways. TOKYO-( BUSINESS WIRE)-Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states.
0 Comments
Leave a Reply. |